Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression

Published:2020-11 Issue: Volume:149 Page:23-32
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Frank Malene Støchkel,Bødtger Uffe,Høegholm Asbjørn,Stamp Inger Merete,Gehl Julie

Funder

Changing Cancer Care

Interreg Deutschland-Denmark supported by the European Regional Development Fund

IMK Almene Fond and Naestved, Slagelse and Ringsted Hospitals’ Research Funds

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference34 articles.

1. Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice;Hotta;Int. J. Clin. Oncol.,2019

2. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N. Engl. J. Med.,2015

3. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N. Engl. J. Med.,2015

4. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial;Rittmeyer;Lancet (London, England),2017

5. Accuracy and consequences of same-day, invasive lung cancer workup - a retrospective study in patients treated with surgical resection;Madsen;Eur. Clin. Respir. J.,2016

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer;Annals of Oncology;2024-10

2. Clinical applications of circulating biomarkers in non-small cell lung cancer;Frontiers in Cell and Developmental Biology;2024-08-21

3. Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC;Journal for ImmunoTherapy of Cancer;2024-04

4. Redetermination of PD-L1 expression after chemio-radiation in locally advanced PDL1 negative NSCLC patients: retrospective multicentric analysis;Frontiers in Oncology;2024-01-31

5. PD-L1 assessment in lung cancer biopsies—pitfalls and limitations;The International Journal of Biological Markers;2023-12-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3